(Q34664767)

3 August 2017

1 reference

title

Essential hypertension. (English)

1 reference

3 August 2017

1 reference

Franz H Messerli

1 reference

ORCID Public Data File 2021

3 August 2017

Bryan Williams

1 reference

author name string

Eberhard Ritz

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

370

1 reference

3 August 2017

issue

9587

1 reference

3 August 2017

page(s)

591-603

1 reference

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Measuring blood pressure: pitfalls and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Comparison of oscillometric blood pressure measurements at the wrist with an upper-arm auscultatory mercury sphygmomanometer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Comparison of wrist blood pressure measurement with conventional sphygmomanometry at a cardiology outpatient clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Task Force II: blood pressure measurement and cardiovascular outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Properly defining white coat hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Short- and Long-Term Incidence of Stroke in White-Coat Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

White coat effect, blood pressure and mortality in men: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

'Reverse white-coat hypertension' in older hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Reversed white-coat hypertension: definition, mechanisms and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Time for focus on morning hypertension: pitfall of current antihypertensive medication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Mechanical Principles in Arterial Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effect of different antihypertensive drug classes on central aortic pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Assessing kidney function--measured and estimated glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Time to abandon microalbuminuria?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Is echocardiography essential in the management of newly diagnosed hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Does hypertension confer a prothrombotic state? Virchow's triad revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The blood coagulation system as a molecular machine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Secondary endothelial dysfunction: hypertension and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Drug therapy for prehypertension questioned

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Impact of high-normal blood pressure on the risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Hypertension—time to move on

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Randomized trials of sodium reduction: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Feasibility of treating prehypertension with an angiotensin-receptor blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Optimisation of antihypertensive treatment by crossover rotation of four major classes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Evolution of hypertensive disease: a revolution in guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Systolic and diastolic blood pressure control in antihypertensive drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Goal-oriented hypertension management: translating clinical trials to practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Characteristics of patients with uncontrolled hypertension in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The role of aldosterone antagonists in the management of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Low-renin status in therapy-resistant hypertension: a clue to efficient treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Primary hyperaldosteronism associated with hypertensive emergencies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Screening for primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Efficacy of Add-On Aldosterone Receptor Blocker in Uncontrolled Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The role of spironolactone in the treatment of patients with refractory hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Noncompliance may cause half of antihypertensive drug "failures"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Resistant hypertension: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Fixed-dose combinations improve medication compliance: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Antihypertensive treatment and the J-curve

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Beta-blockers for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Carotid Intima-Media Thickness and Antihypertensive Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Are calcium antagonists safe?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Do thiazide diuretics confer specific protection against strokes?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Weight and blood pressure. Findings in hypertension screening of 1 million Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Incidence and precursors of hypertension in young adults: the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Relationship among Systolic Blood Pressure, Serum Insulin and Leptin, and Visceral Fat Accumulation in Obese Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Visceral fat in hypertension: influence on insulin resistance and beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Insulin resistance: the shape of things to come.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Blood pressure, cognitive dysfunction, and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Low blood pressure and dementia in elderly people: the Kungsholmen project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Current and remote blood pressure and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Influence of losartan and atenolol on memory function in very elderly hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prognostic significance of left ventricular mass change during treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Incidence of and Risk Factors for Atrial Fibrillation in Older Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Is there an association between hypertension and cancer mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Antihypertensive therapy and the risk of malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Risk factors for renal cell carcinoma: hypertension or diuretics?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

Recent hypertension trials: implications and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

The year in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961299-9

7 January 2021

10.1016/S0140-6736(07)61299-9

Identifiers

DOI

1 reference

3 August 2017

1 reference